S18-000003 (S18-000003) is a potent, selective, orally bioavailable RORγt inhibitor with IC50 of 29 nM (hRORγt, GAL4), shows no significant activity against RORα, RORβ and LXRα/β(IC50>10 uM).

TP0438836 is a potent, low-absorbable sodium-dependent glucose cotransporter (SGLT) inhibitor with IC50 of 28 nM/7 nM for hSGLT1 and hSGLT2, respectively.

DK419 (DK-419) a potent, orally acitve inhibitor of Wnt/β-catenin signaling with IC50 of 0.19 uM in Wnt3A-stimulated TOPFlash assays.

(R)-ND-336 is a potent and selective small-molecule MMP-9 inhibitor with Ki of 19 nM, weakly inhibits MMP-2 and MMP-14 (Ki=127 and 119 nM), poorly inhibits other MMPs (Ki>10 uM).

LIT-001 (LIT001) is the first nonpeptide Oxytocin receptor (OT-R) agonist with EC50 of 55 nM, Emax=96%.

CN427 (CN-427) is novel BRD4 (BD1, 2) inhibitor with IC50 of 66 nM, MV4-11 viability IC50 of 1.1 uM..

VU0529331 (VU 0529331) is the first synthetic small molecule activator of non-GIRK1-containing GIRK (non-GIRK1/X) channels that can specifically modulate the activity of GIRK1-containing GIRK channels..

BTK inhibitor 1 (Compound 27)

NCT-506 is an orally bioavailable aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with an IC50 of 7 nM.

N,N-Diethyl-p-toluamide is a mosquito repellent.

AI3-15902 is a biochemical.

Methyl phenylcarbamate is a biochemical.

Piperonyl butoxide (PBO) is an organic compound used as a component of pesticide formulations. It is a waxy white solid. It is a synergist. That is, despite having no pesticidal activity of its own, it enhances the potency of certain pesticides such as carbamates, pyrethrins, pyrethroids, and rotenone.[1] It is a semisynthetic derivative of safrole.

Ampyrone is a metabolite of AMINOPYRINE with analgesic and anti-inflammatory properties. It is used as a reagent for biochemical reactions producing peroxides or phenols. Ampyrone stimulates LIVER MICROSOMES and is also used to measure extracellular water.

PD-173212 is a small molecule N-type calcium channel blocker.

TTK21 (CBP-p300 activator TTK21) is a small molecule activator of CBP/p300 histone acetyltransferase activity with a maximal effect at a concentration of 275 uM.

A cell-permeable benzochromene that selectively impairs the viability and growth of IGF2-overexpressing hepatocellular carcinoma cells, binds to MFP-2, stimulates the expression of IGFBP-1 and SOCS-3 through activation of STAT6.

A potent, selective, brain penetrant PDE10A inhibitor with Ki of 4 nM.

A potent blocker of voltage-gated potassium channels Kv7 (KCNQ) that enhances ACh release from rat hippocampal slices in vitro with EC50 of 0.7 uM.

Firategrast is an orally bioavailable alpha4 beta1/alpha4 beta7 integrin antagonist designed to reduce trafficking of lymphocytes into the central nervous system (CNS).

CH7057288 (CH-7057288) is a novel potent and selective pan-TRK inhibitor with IC50 of 1.1/7.8/5.1 nM for TRKA/TRKB/TRKC, respectively.

AZD1390 is a first-in-class orally available and CNS penetrant ATM inhibitor with an IC50 of 0.78 nM in cells and >10,000-fold selectivity over closely related members of the PIKK family of enzymes and excellent selectivity across a broad panel of kinases

ITI-214 is a potent, selective phosphodiesterase 1 (PDE1) inhibitor with Ki of 58 pM, displays >1,000-fold selectivity over PDE4A/4D and other PDE isoforms.

Bradanicline (TC-5619) is an experimental pharmaceutical drugthat acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors.

Nelivaptan is a non-peptide vasopressin receptor antagonist that is selective for the V1B subtype.

CM-4620 is a calcium-release activated calcium-channel (CRAC channel) inhibitor, with IC50s of 119 nM, 895 nM for Orai1/STIM1 and Orai2/STIM1 channels, respectively.

HS-38 is a potent and selective DAPK1 and DAPK3 (ZIPK) inhibitor with IC50 of 200 nM for DAPK1 and Kd of 280 nM for ZIPK, also inhibits Pim3 (IC50=200 nM), and displays no activity against Src or Abl, little activity against EGFR;

MG624 is a potent and selective neuronal α7 nAChR antagonist with a Ki of 106 nM.

N2-OH-PhIP is a PhIP metabolite.

GW274150 is a novel arginine-competitive, NADPH-dependent iNOS inhibitor that has been identified from a series of acetamide amino acids that have a high selectivity for iNOS vs both eNOS (> 260-fold) and nNOS (> 219-fold) and high bioavailability (> 90%) after oral administration.Target: iNOSin vivo: GW274150 demonstrates a narrow neuroprotective therapeutic window against the toxic actions of 6-OHDA. GW274150 administration leads to a dose-dependent decrease in the number of iNOS-positive cells in the SNc of the 6-OHDA-lesioned animals. The iNOS inhibitor GW274150 fails to produce long-term neuroprotection after its withdrawal in the 6-OHDA-lesioned rat. [1]